Insmed (INSM) Cash from Financing Activities (2010 - 2026)

Insmed has reported Cash from Financing Activities for 17 years, with the latest figure at $27.2 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 96.83% year-over-year to $27.2 million in Q2 2026; TTM through Jun 2026 was $124.0 million, a 91.41% decrease from a year earlier, with the FY2025 full-year figure at $954.1 million, down 28.85% from the prior year.
• Cash from Financing Activities was $27.2 million for Q2 2026 at Insmed, down from $29.5 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $857.8 million in Q2 2025, with the low at -$399000.0 in Q1 2023.
• Average Cash from Financing Activities over 5 years is $184.1 million, with a median of $33.6 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities plunged 106.18% in 2023, then soared 31701.44% in 2024.
• Over 5 years, Cash from Financing Activities stood at $743.4 million in 2022, then plunged by 83.42% to $123.3 million in 2023, then advanced by 29.24% to $159.3 million in 2024, then slumped by 78.75% to $33.9 million in 2025, then decreased by 19.73% to $27.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $27.2 million (Q2 2026), $29.5 million (Q1 2026), and $33.9 million (Q4 2025), per Business Quant data.